Results 1 to 10 of about 641,621 (255)
Surgical Oncology Clinics of North America, 2021 Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer, with approximately 60 430 new diagnoses expected in 2021 in the US. The incidence of PDAC is increasing by 0.5% to 1.0% per year, and it is projected to become the second-leading cause of cancer-related mortality by 2030.Effective screening is not available for PDAC, and most ...
Akhil Chawla +3 more
+6 more sources
European Journal of Surgical Oncology, 2023 The need for a common education and training track in surgical oncology across Europe has been emphasized. ESSO provides several hands-on courses for skills training and face-to-face discussions. The core curriculum provides a framework for the overall theoretical requirements in surgical oncology. The UEMS/EBSQ fellowship exam is designed to test core
Kjetil Søreide +4 more
openaire +6 more sources
Journal of Hematology & Oncology, 2022 Many types of human cells self-destruct to maintain biological homeostasis and defend the body against pathogenic substances. This process, called regulated cell death (RCD), is important for various biological activities, including the clearance of ...
Xuhui Tong +8 more
doaj +1 more source
Oncogenesis, 2022 Pancreatic ductal adenocarcinoma (PDAC) is a well-known lethal and heterogeneous disease. Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) is an important mutagenic driver that has seldom been investigated in PDAC. Therefore, this
Yunzhen Qian +13 more
doaj +1 more source
World Journal of Surgical Oncology, 2021 Background Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the first rate-limiting enzyme of the hexosamine biosynthesis pathway (HBP), which plays a pivotal role in the progression of pancreatic ductal adenocarcinoma (PDAC).
Yitao Gong +11 more
doaj +1 more source
CA: A Cancer Journal for Clinicians, 1994 Pancreatic cancer is a devastating disease for the patient and presents challenging diagnostic and management problems for the physician. A range of serologic and radiologic studies are available for evaluation and staging of this disease. However, invasive studies, including laparotomy, are often necessary to establish the diagnosis and resectability.
Michel G. Sarr +3 more
openaire +3 more sources
World Journal of Surgical Oncology, 2022 Background Intraductal papillary mucinous neoplasms (IPMNs) are characterized by their abundant mucin production and malignant potential. IPMNs of the pancreas are mainly managed according to their radiographic indications, but this approach lacks ...
Yunzhen Qian +12 more
doaj +1 more source
Cancer Control, 2020 Lymphatic metastasis is a major determinant of the outcome of resected pancreatic cancer. Gemcitabine-based adjuvant chemotherapy can improve the outcome of resected pancreatic cancer.
Chen Liu MD, PhD +10 more
doaj +1 more source